Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
NCT00920205
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
26
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
MPC-3100 (an Hsp90 inhibitor)
Sponsor
Myrexis Inc.